证券日报网讯12月9日，泓博医药（301230）在互动平台回答投资者提问时表示，截至2025年11月28日 (11月最后一个交易日)，公司的股东户数为14648户。 ...

Core Viewpoint - The company acknowledges the recent decline in stock price over the past five months, attributing it to multiple factors including macroeconomic environment, industry cycles, and market sentiment [1] Group 1: Stock Performance and Investor Concerns - The company has experienced a continuous stock price decline for five months, which investors are concerned may be linked to shareholder unlocks and reductions [1] - The management emphasizes that stock price fluctuations are market behaviors and not solely reflective of the company's performance [1] Group 2: Company Outlook and Management Response - The company reports stable operations and ongoing positive business development, with management expressing confidence in future growth [1] - The company is committed to focusing on its core business and improving operational quality and profitability to create long-term sustainable value for investors [1] - The management will consider investor suggestions and will disclose any relevant plans in a timely manner [1]

Group 1 - The core viewpoint of the article is that Hongbo Pharmaceutical (301230.SZ) has confirmed that Palivizumab is one of its commercialized products, which is suitable for treating influenza caused by common seasonal flu, type A influenza, or type B influenza [1]

Core Viewpoint - Hongbo Pharmaceutical (301230.SZ) has indicated that Palivizumab is one of its commercialized products, suitable for treating influenza viruses causing common influenza, type A influenza, or type B influenza [1] Group 1 - Hongbo Pharmaceutical's product Palivizumab is aimed at addressing various types of influenza viruses [1]

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [2] Core Views - The pharmaceutical and biotechnology industry index experienced a decline of 4.40%, ranking 23rd among 31 primary industries, underperforming the CSI 300 index which fell by 2.19% [6][18] - The valuation of the pharmaceutical and biotechnology industry as of November 28, 2025, is a PE (TTM overall method, excluding negative values) of 29.46x, down from 30.89x in the previous period, indicating a downward trend and below the average [22] - The report highlights potential beneficiaries from the upcoming ASH data, particularly in blood diseases and companies with solid grassroots channels, as well as those with differentiated advantages in oncology, autoimmune, and rare disease products [10] Summary by Sections Industry Review - The pharmaceutical and biotechnology industry index fell by 4.40%, with chemical preparations and medical devices showing declines of 2.86% and 2.95% respectively, while offline pharmacies and vaccines saw larger declines of 8.22% and 6.42% [6][18] - The PE ratio for the pharmaceutical and biotechnology industry is 29.46x, with the highest valuations in the vaccine (47.56x), hospital (41.17x), and medical device (36.77x) sectors, while pharmaceutical circulation has the lowest at 14.58x [22] Important Industry News - The National Administration of Traditional Chinese Medicine and the National Healthcare Security Administration released a directory for traditional Chinese medicine diseases suitable for disease-based payment [26][27] - AstraZeneca's drug "Durvalumab" received FDA approval for a new indication in perioperative treatment of gastric cancer [32] - Otsuka Pharmaceutical's new drug for IgA nephropathy, "Sibeprenlimab," has been approved by the FDA [38] - Bayer's first-in-class lung cancer drug "Sevabertinib" has been approved by the FDA for specific patient populations [40] Investment Recommendations - Focus on innovative pharmaceutical companies that may benefit from the medical insurance or commercial insurance directories, blood cancer targets with imminent ASH data releases, and biotech and CXO leaders with solid technology platforms and international collaboration expectations [10]

Core Viewpoint - The AI medical sector experienced a significant increase of 3.48% on November 24, with leading stock performance from Sichuang Medical [1] Group 1: Market Performance - On November 24, the Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] - The top-performing stocks in the AI medical sector included Sichuang Medical, which rose by 8.20% to a closing price of 4.88, and Chengdu Xian Dao, which increased by 6.61% to 22.90 [1] Group 2: Trading Volume and Capital Flow - The AI medical sector saw a net inflow of 136 million yuan from institutional investors, while retail investors contributed a net inflow of approximately 99.92 million yuan [1] - The trading volume for Sichuang Medical reached 2.345 million shares, with a transaction value of 1.11 billion yuan [1] Group 3: Individual Stock Capital Flow - Notable net inflows from institutional investors included 67.19 million yuan for Weining Health, 38.08 million yuan for Rundar Medical, and 33.69 million yuan for Jiuyuan Yinhai [2] - Conversely, retail investors showed net outflows in several stocks, including 47.88 million yuan for Weining Health and 55.12 million yuan for Jiuyuan Yinhai [2]

Core Viewpoint - Hongbo Pharmaceutical's stock increased by 5.06% to 30.94 CNY per share, with a total market capitalization of 4.319 billion CNY as of November 24 [1] Company Overview - Hongbo Pharmaceutical, established on December 14, 2007, is located in the Pudong New Area of Shanghai and was listed on November 1, 2022 [1] - The company's main business includes drug discovery, pharmaceutical process research and development, and commercial production of raw material intermediates [1] - Revenue composition: Drug discovery accounts for 52.67%, commercial production 35.00%, process research and development 8.10%, and other activities 4.23% [1] Shareholder Information - Changcheng Fund's Changcheng Consumption Value Mixed A (200006) is among the top ten circulating shareholders of Hongbo Pharmaceutical, holding 1.6009 million shares, unchanged from the previous period, representing 2.08% of circulating shares [2] - The fund has an estimated floating profit of approximately 2.3854 million CNY as of today [2] Fund Performance - Changcheng Consumption Value Mixed A (200006) was established on April 6, 2006, with a current scale of 516 million CNY [2] - Year-to-date return is 14.39%, ranking 4459 out of 8209 in its category; one-year return is 6.92%, ranking 5776 out of 8129; and since inception, the return is 232.84% [2] Fund Manager Information - The fund manager of Changcheng Consumption Value Mixed A is Long Yufei, who has been in the position for 8 years and 40 days [3] - The total asset size of the fund is 843 million CNY, with the best return during the tenure being 61.42% and the worst return being -8.9% [3] Fund Holdings - Changcheng Consumption Value Mixed A (200006) has Hongbo Pharmaceutical as its sixth-largest holding, with 1.6009 million shares, accounting for 6.61% of the fund's net value [4] - The estimated floating profit for the fund from this holding is approximately 2.3854 million CNY [4]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Views - The report emphasizes three core investment directions: 1) Breakthroughs in cutting-edge technologies (e.g., First-in-class drugs in oncology, weight loss, autoimmune fields, and innovative devices like brain-machine interfaces); 2) Clinical validation and commercialization potential (focus on the progress of domestic innovative drugs going abroad and the clinical development progress post-BD transactions); 3) Efficiency advantages in the industry chain (CXO leaders and high-value consumables' global layout) [8] Industry Review - The pharmaceutical and biotechnology industry index increased by 0.81%, ranking 21st among 31 primary industries, outperforming the CSI 300 index which decreased by 0.27% [5][16] - The sub-industries of pharmaceutical circulation and in vitro diagnostics saw significant gains of 7.61% and 5.32% respectively, while medical research outsourcing and medical devices experienced declines of 3.49% and 1.76% [5][16] - As of November 14, 2025, the industry PE (TTM overall method, excluding negative values) was 30.89x, up from 30.67x in the previous period, indicating an upward valuation trend that remains below the average [21] - The top three PE ratios among the sub-industries were for vaccines (50.42x), hospitals (43.67x), and medical devices (37.84x), while pharmaceutical circulation had the lowest valuation at 15.46x [21] Important Industry News - The National Health Commission and others issued implementation opinions to promote and regulate the application of "AI + healthcare" [7] - The NMPA released a new version of the "Medical Device Production Quality Management Specifications" [7] - Novartis received NMPA approval for its first radioligand therapy drug "Pluvicto®" for dual indications [7] - Sanofi's innovative targeted nano-antibody "Cablivi®" was approved by NMPA for treating immune-mediated thrombotic thrombocytopenic purpura [7] - The U.S. government reached a drug price control agreement with Eli Lilly and Novo Nordisk, leading to significant price reductions for GLP-1 drugs [7]

证券代码：301230 证券简称：泓博医药 公告编号：2025-064 上海泓博智源医药股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在新增、修改、否决议案的情形； 2、本次股东会不存在变更前次股东会决议的情形； 3、本次股东会采取现场投票与网络投票相结合的方式进行。 一、会议召开情况 1、会议通知方式：公告方式 2、会议召开时间： （1）现场会议召开时间：2025 年 11 月 14 日（星期五）14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 11 月 14 日上午 9:15~9:25，9:30~11:30 和下午 13:00~15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为 2025 年 11 月 14 日 9:15～15:00 任意时间。 3、现场会议地点：上海浦东新区凯庆路 59 号 12 幢公司一楼会议室 4、会议召开方式：本次股东会采取现场投票、网络投票相结合的方式。 6、现场会议主持人：公司董事长 Pin ...

致：上海泓博智源医药股份有限公司 北京市嘉源律师事务所 关于上海泓博智源医药股份有限公司 2025 年第三次临时股东会的 北京市嘉源律师事务所 关于上海泓博智源医药股份有限公司 2025 年第三次临时股东会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 北京 BEIJING·上海 SHANGHAI·深圳 SHENZHEN·香港 HONG KONG·广州 GUANGZHOU·西安 XI'AN 法律意见书 嘉源(2025)-04-823 北京市嘉源律师事务所（以下简称"本所"）接受上海泓博智源医药股份有 限公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《上市公司股东会规则》（以下简称"《股东会规则》"）等现行有效 的法律、行政法规、部门规章、规范性文件（以下简称"法律法规"）以及《上 海泓博智源医药股份有限公司章程》（以下简称"《公司章程》"）的有关规定，指 派本所律师对公司 2025 年第三次临时股东会（以下简称"本次股东会"）进行见 证，并依法出具本法律意见书。 为出具本法律意见书，本所指派律师现场见证了本次股东会，查阅了公司提 供的与本次 ...